Pfizer Scoops 3SBio’s PD-1/VEGF Bispecific In ADC Combo Push

 
• By Dexter Jie Yan
  
3SBio's bispecific antibody SSGJ-707 meets Pfizer's quest for another immuno-oncology therapy to assess in combination with its in-house ADCs. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business